Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Vesicare
|
| gptkbp:activities |
muscarinic receptor antagonist
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
gptkb:Vesicare
|
| gptkbp:clinical_trial |
Phase III
symptomatic relief treatment of urinary incontinence |
| gptkbp:contraindication |
gptkb:sneaker
gptkb:Insurance_Company urinary retention |
| gptkbp:counseling_services |
avoid alcohol
stay hydrated take with or without food do not crush or chew report severe side effects |
| gptkbp:developed_by |
gptkb:Astellas_Pharma
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
extended-release tablet
|
| gptkbp:has_ability |
10 mg
5 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
solifenacin succinate
|
| gptkbp:ingredients |
C23 H26 N2 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors other anticholinergic drugs |
| gptkbp:is_atype_of |
G04 B D08
|
| gptkbp:is_used_for |
overactive bladder
|
| gptkbp:lifespan |
45 hours
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Japan gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:provides_information_on |
not recommended for children
recommended for adults |
| gptkbp:research_focus |
patient adherence
combination therapies new formulations long-term efficacy side effect management |
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea abdominal pain constipation dry mouth blurred vision urinary retention |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
204255-11-8
|